Você procurou por: glikozilkeramīda (Letão - Inglês)

Šis enzīms palīdz organismam kontrolēt glikozilkeramīda līmeni.
this enzyme helps the body control levels of glucosylceramide.

gošē slimības gadījumā glikozilkeramīda līmenis var pārmērīgi paaugstināties.
in gaucher disease glucosylceramide levels can get too high.

in vitro glikozilkeramīda sintāzi inhibē miglustats ar 20- 37 µm ic50.
in vitro, glucosylceramide synthase is inhibited by miglustat with an ic50 of 20-37 µm.

inhibitora darbība uz glikozilkeramīda sintēzi veido pamatu substrāta samazināšanas terapijai gošē slimības gadījumā.
in addition, inhibitory action on a non-lysosomal glycosylceramidase has been demonstrated experimentally in vitro the inhibitory action on glucosylceramide synthase forms the rationale for substrate reduction therapy in gaucher disease.

miglustats ir glikozilkeramīda sintāzes, kas atbild par pirmo soli lielākās daļas glikolipīdu sintēzē, inhibitors.
miglustat is an inhibitor of glucosylceramide synthase, the enzyme responsible for the first step in the synthesis of most glycolipids.

zavesca darbības pamatā ir enzīma glikozilkeramīda sintāzes inhibīcija, kas atbild par pirmo etapu gandrīz visu glikosfingolipīdu sintēzē.
zavesca works by inhibiting the enzyme called ‘glucosylceramide synthase’ which is responsible for the first step in the synthesis of most glycosphingolipids.

tipa gošē slimības gadījumā, no jūsu organisma netiek izdalīta viela, kuras nosaukums ir glikozilkeramīds.
in type 1 gaucher disease, a substance called glucosylceramide is not removed from your body.